

Oral Antibiotics Market Expected to Reach \$23,306.10 million by 2027- Allied Market Research

Even though Covid-19 is a viral infection, the overlapping radiological and clinical features with bacterial respiratory tract infection demand oral antibiotics

NE WIN SIVERS DRIVE, PROVINCE: -
PORTLAND, UNITED STATES,
September 27, 2021 /

EINPresswire.com/ -- Allied Market Research recently published a report, "[Oral Antibiotics Market](#) by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired

Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 2019–2027". According to the report, the global oral antibiotics

industry was pegged at \$18.36 billion in 2018, and is anticipated to reach \$23.30 billion by 2027, growing at a CAGR of 2.7% from 2019 to 2027.

“

Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS)”

Allied Market Research

Major drivers of market growth

Rise in consumption in low- and middle-income countries, surge in prevalence of infectious diseases, and development of novel approaches have boosted the growth of the global oral antibiotics market. However, development of antibiotic resistance and time-consuming approvals hamper the market. On the contrary, discovery

of advanced therapies to treat antibiotic-resistance is expected to create lucrative opportunities for the market players in the coming years.



(A PDF | Sample Of The Report Is Available Immediately Upon Request)@
<https://www.alliedmarketresearch.com/request-sample/6905>

COVID-19 scenario:

Even though Covid-19 is a viral infection, the overlapping radiological and clinical features with bacterial respiratory tract infection demand oral antibiotics.

Several virologists claim that prescribing antibiotics for Covid-19 patients could create more resilient virus, which decreased the demand for antibiotics.

The beta lactam & beta lactamase inhibitors segment dominated market

By class, the beta lactam & beta lactamase inhibitors segment held the largest share in 2018, accounting for more than three-fifths of the global oral antibiotics market, owing to its broad-spectrum of activity, which is effective on several group of bacterial infections. However, the quinolone segment is projected to register the highest CAGR of 3.8% during the forecast period, due to its broad spectrum of activity, which gives immense opportunities to pharmaceutical companies for innovations.

Get Detailed COVID-19 Impact Analysis on the Oral Antibiotics Market @

<https://www.alliedmarketresearch.com/request-for-customization/6905?reqfor=covid>

The community-acquired respiratory tract infections (CARTIS) segment to portray highest CAGR through 2027

By the community-acquired respiratory tract infections (CARTIS) segment to manifest the highest CAGR of 4.1% during the forecast period, owing to increase in prevalence of infectious diseases and need for development of oral antibiotics. However, the urinary tract infections (UTIs) segment held the largest held the largest share in 2018, contributing to more than one-third of the global oral antibiotics market, due to increase in prevalence of UTIs because of factors such as pelvic prolapse, lack of estrogen, and loss of lactobacilli in vaginal flora.

Asia-Pacific, followed by Europe and Asia-Pacific, held the lion's share

By region, the market across Asia-Pacific dominated in 2018, contributing to nearly two-fifths of the market, due to large number of antibiotics consumption, easy availability of antibiotics, and rise in sales of antibiotics without prescription. However, the global oral antibiotics market across LAMEA is expected to register the highest CAGR of 3.7% during the forecast period. This is attributed to easy obtainability of over-the-counter antibiotics. Also, there are no legislations or restrictions on their use in this region.

Interested to Procure the Data? Inquire here @ <https://www.alliedmarketresearch.com/purchase-enquiry/6905>

Major market players

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Allergan Plc.
Merck & Co. Inc.
GlaxoSmithKline plc
Novartis International AG (Sandoz)
Mylan N.V.
Sanofi
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

<https://www.alliedmarketresearch.com/avenue/trial/starter>

Get more information: <https://www.alliedmarketresearch.com/library-access>

Similar Exclusive Reports:

[VR in Healthcare Market](#) - Global Opportunity & Industry Forecast, 2026

[Immunosuppressant Market](#) - Global Opportunity & Industry Forecast, 2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain

concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: <https://www.alliedmarketresearch.com>

Follow Us on LinkedIn: <https://www.linkedin.com/company/allied-market-research>

David Correa

Allied Analytics LLP

+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/552393946>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.